Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials-Reference-Cited by-同舟云学术

Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials

Published:2020-09-07 Issue:2 Volume:35 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Beck L.A.¹^ORCID,Silverberg J.I.²³⁴⁵^ORCID,Simpson E.L.⁶,Yosipovitch G.⁷^ORCID,Eckert L.⁸^ORCID,Guillemin I.⁹,Chen Z.¹⁰,Ardeleanu M.¹⁰,Plaum S.¹¹,Graham N.¹⁰,Ruddy M.¹⁰,Pirozzi G.¹¹,Gadkari A.¹⁰

Affiliation:

1. Department of Dermatology University of Rochester Medical Center Rochester NY USA

2. Department of Dermatology The George Washington School of Medicine and Health Sciences Washington DC USA

3. Department of Preventive Medicine Feinberg School of Medicine Northwestern University Chicago IL USA

4. Department of Medical Social Sciences Feinberg School of Medicine Northwestern University Chicago IL USA

5. Northwestern Medicine Multidisciplinary Eczema Center Chicago IL USA

6. Department of Dermatology Oregon Health and Science University Portland OR USA

7. Miami Itch Center Dr Phillip Frost Department of Dermatology & Cutaneous Surgery University of Miami Miller School of Medicine Miami FL USA

8. Sanofi Chilly‐Mazarin France

9. Sanofi Lyon France

10. Regeneron Pharmaceuticals Tarrytown NY USA

11. Sanofi Bridgewater NJ USA

Funder

Sanofi

Regeneron Pharmaceuticals

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16865

Reference10 articles.

1. Illness perception in individuals with atopic dermatitis

2. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

3. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

4. Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase 3 clinical trial (LIBERTY AD CAFE);Bruin‐Weller M;Br J Dermatol,2017

5. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study;Journal of the American Academy of Dermatology;2024-07

2. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs;Allergy;2024-01-08

3. Assessment and Management of Sleep Disturbances in Atopic Dermatitis: A Review;Dermatitis®;2023-09-27

4. A detailed evaluation of the effect of dupilumab on sleep in adults with atopic dermatitis;British Journal of Dermatology;2023-09-02

5. Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study;British Journal of Dermatology;2023-08-10